Cargando…

Susceptibility-guided vs. empirical 10-day quadruple treatment for Helicobacter pylori-infected patients: A prospective clinical trial of first-line therapy

BACKGROUND: The increasing antimicrobial resistance of Helicobacter pylori (H. pylori) has resulted in a fall in cure rates. We aimed to assess the effectiveness of first-line susceptibility-guided therapy and furazolidone-based quadruple therapy for H. pylori-infected patients. METHODS: Subjects wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Peiwei, Jin, Jing, Chen, Yan, Ma, Jianjuan, Du, Qin, Han, Yuehua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490362/ https://www.ncbi.nlm.nih.gov/pubmed/36160235 http://dx.doi.org/10.3389/fmicb.2022.973975

Ejemplares similares

Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis
por: Nyssen, Olga P., et al.
Publicado: (2022)

Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections
por: Yang, Tiankuo, et al.
Publicado: (2020)

Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: A comparative, open trial
por: Choi, Youn I, et al.
Publicado: (2019)

Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication
por: Huang, Hsiang Tso, et al.
Publicado: (2018)

Susceptibility-Guided Therapy vs. Bismuth-Containing Quadruple Therapy as the First-Line Treatment for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis
por: Ouyang, Yaobin, et al.
Publicado: (2022)

Shifts in the Human Gut Microbiota Structure Caused by Quadruple Helicobacter pylori Eradication Therapy
por: Olekhnovich, Evgenii I., et al.
Publicado: (2019)

Efficacy of Twice a Day Bismuth Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection
por: Kim, Jeemyoung, et al.
Publicado: (2022)

Empiric “Three-in-One” Bismuth Quadruple Therapy for Second-Line Helicobacter pylori Eradication: An Intervention Study in Southern Italy
por: Losurdo, Giuseppe, et al.
Publicado: (2022)

Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial
por: Masoodi, Mohsen, et al.
Publicado: (2015)

Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed Helicobacter pylori Infection as 14 Days of Bismuth-Based Quadruple Therapy
por: Moon, Sang-Gon, et al.
Publicado: (2022)

Correlation Analysis Among Genotype Resistance, Phenotype Resistance, and Eradication Effect After Resistance-Guided Quadruple Therapies in Refractory Helicobacter pylori Infections
por: Guo, Zijun, et al.
Publicado: (2022)

Sequential Therapy vs Quadruple Therapy for Helicobacter pylori Eradication in South West of Iran
por: Masjedizadeh, Abdol Rahim, et al.
Publicado: (2014)

Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection
por: Jheng, Guang-Hong, et al.
Publicado: (2015)

Effects of 14-days bismuth- and tetracycline-containing quadruple therapy with concomitant regimen for the first line Helicobacter pylori eradication
por: Kazemi Veysari, Arash, et al.
Publicado: (2023)

Empirical or susceptibility-guided treatment for Helicobacter pylori infection? A comprehensive review
por: Gisbert, Javier P.
Publicado: (2020)

Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial
por: Hajiani, Eskandar, et al.
Publicado: (2018)

Success of 14-day triple and quadruple therapy for the control of Helicobacter pylori infections in Kohat district
por: Shah, Syed Fahim, et al.
Publicado: (2022)

Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes
por: Kim, Sung Eun, et al.
Publicado: (2017)

Lactobacillus rhamnosus GG supplementation on eradication rate and dyspepsia in Helicobacter pylori infection treated with three-in-one bismuth quadruple therapy
por: Marinelli, Paride, et al.
Publicado: (2022)

Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori
por: Zhang, Lingyun, et al.
Publicado: (2019)

Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection
por: Lee, Seong tae, et al.
Publicado: (2015)

Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade “A” Success Rate for First-Line Helicobacter pylori Eradication
por: Tai, Wei-Chen, et al.
Publicado: (2015)

A Simplified Low-Dose 10-Day Quadruple Therapy with a Galenic Formulation of Bismuth Salicylate Is Highly Effective for Helicobacter pylori Eradication
por: Dore, Maria Pina, et al.
Publicado: (2023)

Impact of previous metronidazole exposure on metronidazole-based second-line quadruple therapy for Helicobacter pylori infection
por: Lee, Gil Ho, et al.
Publicado: (2020)

Corrigendum to “Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori”
por: Zhang, Lingyun, et al.
Publicado: (2021)

Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori
por: Gisbert, Javier P, et al.
Publicado: (2012)

Comparison of quadruple and triple Furazolidone containing regimens on eradication of helicobacter pylori
por: Mokhtare, Marjan, et al.
Publicado: (2015)

Effects of Clarithromycin-Containing Quadruple Therapy on Helicobacter Pylori Eradication after Nitroimidazole-Containing Quadruple Therapy Failure
por: Fakheri, Hafez, et al.
Publicado: (2016)

Multiple Genetic Analysis System-Based Antibiotic Susceptibility Testing in Helicobacter pylori and High Eradication Rate With Phenotypic Resistance-Guided Quadruple Therapy
por: Dong, Fangyuan, et al.
Publicado: (2015)

Quadruple therapy with vonoprazan 20 mg daily as a first‐line treatment for Helicobacter pylori infection: A single‐center, open‐label, noninferiority, randomized controlled trial
por: Lu, Lifen, et al.
Publicado: (2022)

Egg yolk antibody combined with bismuth-based quadruple therapy in Helicobacter pylori infection rescue treatment: a single-center, randomized, controlled study
por: Cheng, Sha, et al.
Publicado: (2023)

Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial
por: Kim, Young-Il, et al.
Publicado: (2021)

Bacteriophages of Helicobacter pylori
por: Muñoz, Angela B., et al.
Publicado: (2020)

Clarithromycin versus Gemifloxacin in Quadruple Therapeutic Regimens for Helicobacter Pylori Infection Eradication
por: Mansour-Ghanaei, Fariborz, et al.
Publicado: (2017)

Effect of gastric microbiota on quadruple Helicobacter pylori eradication therapy containing bismuth
por: Niu, Zhan-Yue, et al.
Publicado: (2021)

Which is the best choice for Helicobacter pylori eradication? Dual therapy or quadruple therapy?
por: Bacaksız, Elif Gram, et al.
Publicado: (2022)

Effects of Quadruple Therapy Combined with Probiotics on Helicobacter Pylori-Related Peptic Ulcer
por: Zhou, Ye, et al.
Publicado: (2022)

Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication
por: Zhang, Ya-Wen, et al.
Publicado: (2018)

Levofloxacin-containing triple therapy versus bismuth-based quadruple therapy as regimens for second line anti- Helicobacter pylori
por: Seyyedmajidi, Mohamadreza, et al.
Publicado: (2019)

Comparison of Azithromycin and Metronidazole in a Quadruple-Therapy Regimen for Helicobacter pylori Eradication in Dyspepsia
por: Agah, Shahram, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ueooo6fs4kod1smg23o3j33t6t